Skip to content

Nevirapine safe and effective in patients with a CD4 cell count below 200

Rifampicin and pyrazinamide treatment for latent TB in HIV patients does not carry high risk of liver injury, but editorial still urges caution

Early liver enzyme elevations wane with prolonged HAART treatment in women with HCV

Final APRICOT and ACTG 5071 HIV/HCV coinfection results published

Report of rare atazanavir-related liver side-effect published

Treatment Action Group releases policy recommendations on HIV/hepatitis C coinfection

Case report shows importance of expert prescribing for patients coinfected with HIV/HBV

Fluconazole doubles nevirapine levels, greatly increasing risk of liver toxicity

Nevirapine liver toxicity associated with CD4 percentage over 25% and genetic factors, rash alone with genetic factors only